BC Week In Review | Dec 7, 2015
Clinical News

CGS-125: Clinical trial started

CapGenesis began a double-blind, placebo-controlled, Dominican Republic clinical trial to evaluate topical CGS-125 in about 48 patients with OA of both knees. CapGenesis Therapeutics LLC , Bethesda, Md.   Product: CGS-125   Business: Autoimmune   Molecular...
Items per page:
1 - 1 of 1